Bifidobacterium Supplementation for Very Low Birth Weight Infants

NCT ID: NCT01375309

Last Updated: 2012-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

246 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Probiotic supplementation to preterm infants have been reported to be beneficial in neonatal intensive care unit (NICU). Our pilot study also showed accelerated feeding in preterm infants who received Bifidobacterium bifidum early after birth. In order to evaluate these beneficial effects of Bifidobacterium bifidum, a prospective randomized control study is conducted. The hypothesis of the study is that Bifidobacterium bifidum supplementation to preterm infants improve enteral feeding and growth in very low birth weight infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Infants

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

probiotics preterm infants enteral feeding Bifidobacterium on enteral feeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Bifidobacterium bifidum

Group Type ACTIVE_COMPARATOR

Bifidobacterium bifidum supplementation

Intervention Type DIETARY_SUPPLEMENT

Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day

Placebo

Dextrin without Bifidobacterium bifidum

Group Type PLACEBO_COMPARATOR

Placebo contains dextrin

Intervention Type DIETARY_SUPPLEMENT

0.5 of dextrin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bifidobacterium bifidum supplementation

Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day

Intervention Type DIETARY_SUPPLEMENT

Placebo contains dextrin

0.5 of dextrin

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bifidobacterium bifidum OLB6378

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants with birth weight less than 1500g

Exclusion Criteria

* Sever bacteremia
* Congenital anomaly
* Not suitable for the trial defined by an attending neonatologist
Maximum Eligible Age

48 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tokyo Women's Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Satoshi Kusuda

Professor of Neonatology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Satoshi Kusuda, MD

Role: PRINCIPAL_INVESTIGATOR

Tokyo Women's Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tokyo Women's Medical Unversity

Shinjuku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

References

Explore related publications, articles, or registry entries linked to this study.

Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database Syst Rev. 2023 Jul 26;7(7):CD005496. doi: 10.1002/14651858.CD005496.pub6.

Reference Type DERIVED
PMID: 37493095 (View on PubMed)

Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database Syst Rev. 2020 Oct 15;10(10):CD005496. doi: 10.1002/14651858.CD005496.pub5.

Reference Type DERIVED
PMID: 33058137 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMIN000002543

Identifier Type: OTHER

Identifier Source: secondary_id

1675

Identifier Type: -

Identifier Source: org_study_id